Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Carmen Garnacho"'
Autor:
Carmen Garnacho, Silvia Muro
Publikováno v:
Journal of Drug Targeting. 25:786-795
Enzyme replacement is a viable treatment for diseases caused by genetic deficiency of lysosomal enzymes. However, suboptimal access of enzymes to target sites limits this strategy. Polymer nanocarriers (NCs) coated with antibody against intercellular
Publikováno v:
Molecular Pharmaceutics
Drugs often use endocytosis to achieve intracellular delivery, either by passive uptake from the extracellular fluid or by active targeting of cell surface features such as endocytic receptors. An example is enzyme replacement therapy, a clinically p
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy. 25(7)
Acid sphingomyelinase deficiency in type B Niemann-Pick disease leads to lysosomal sphingomyelin storage, principally affecting lungs, liver, and spleen. Infused recombinant enzyme is beneficial, yet its delivery to the lungs is limited and requires
Publikováno v:
Biomaterials. 34:3459-3466
Modification of drug delivery nanomaterials with affinity molecules that facilitate targeting, has rendered a new class of ligands for cell receptors, which often possess valency and dimensions different from natural counterparts. Designing strategie
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 340:638-647
Intercellular adhesion molecule-1 (ICAM-1), a transmembrane glycoprotein expressed on activated endothelium and many other cells, represents a suitable target for delivery of drug nanocarriers (NCs) to disease areas. Numerous works have shown efficie
Publikováno v:
Journal of Controlled Release. 130:226-233
Coupling drug carriers to antibodies for targeting endothelial cells (ECs) may improve treatment of vascular and pulmonary diseases. Selecting antibodies that deliver carriers to the cell surface or intracellularly may further optimize specificity of